Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Shanghai Hile Bio-Technology CoSHSE:603718 -1.02%50 Return-on-Tangible-Equity is 6.00% as of Mar. 2026, which is 18% below its 10-year median of 7.33. GuruFocus rates SHSE:603718 with a GF Score™ of 50/100 and a GF Value™ of ¥4.24 (Possible Value Trap). The stock has 5 warning signs investors should review. Among 1,199 Biotechnology companies, Shanghai Hile Bio-Technology Co ranks worse than 62.55% on this metric.
The historical rank and industry rank for Shanghai Hile Bio-Technology Co's Return-on-Tangible-Equity or its related term are showing as below:
SHSE:603718'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -68.3 Med: 7.33 Max: 23.57
Current: -68.3
During the past 13 years, Shanghai Hile Bio-Technology Co's highest Return-on-Tangible-Equity was 23.57%. The lowest was -68.30%. And the median was 7.33%.
SHSE:603718's Return-on-Tangible-Equity is ranked worse than 62.55% of 1199
companies
in the Biotechnology industry
Industry Median: -42.21
vs SHSE:603718: -68.30
Shanghai Hile Bio-Technology Co (SHSE:603718) Return-on-Tangible-Equity Explanation
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Shanghai Hile Bio-Technology Co Return-on-Tangible-Equity Related Terms
Shanghai Hile Bio-Technology Co Return-on-Tangible-Equity Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Shanghai Hile Bio-Technology Co Return-on-Tangible-Equity Chart
SHSE:603718 vs VRTX, REGN, RVMD: Return-on-Tangible-Equity Comparison
For the Biotechnology subindustry, Shanghai Hile Bio-Technology Co's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Shanghai Hile Bio-Technology Co Return-on-Tangible-Equity vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Shanghai Hile Bio-Technology Co's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Shanghai Hile Bio-Technology Co's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 6.00% mean?
Shanghai Hile Bio-Technology Co (SHSE:603718) has a Return-on-Tangible-Equity of 6.00% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Shanghai Hile Bio-Technology Co and its competitors. This is 18% below median its historical median of 7.33. According to the industry distribution chart, Shanghai Hile Bio-Technology Co ranks #750 out of 1199 companies in the Biotechnology industry, placing it in the top 62.6%.
Is Shanghai Hile Bio-Technology Co's Return-on-Tangible-Equity too high?
Shanghai Hile Bio-Technology Co's current Return-on-Tangible-Equity of 6.00% is 18% below median its 10-year median of 7.33. Based on the distribution chart, Shanghai Hile Bio-Technology Co ranks #750 out of 1199 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Shanghai Hile Bio-Technology Co has a GF Score™ of 50/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Shanghai Hile Bio-Technology Co's Return-on-Tangible-Equity compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Shanghai Hile Bio-Technology Co ranks #750 out of 1199 companies for Return-on-Tangible-Equity. This places Shanghai Hile Bio-Technology Co in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Biotechnology company?
A good Return-on-Tangible-Equity depends on the Biotechnology industry context. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Shanghai Hile Bio-Technology Co and its competitors. Shanghai Hile Bio-Technology Co's current Return-on-Tangible-Equity is 6.00%, which is 18% below median its own 10-year median of 7.33. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Shanghai Hile Bio-Technology Co stock overvalued right now?
Based on GuruFocus' analysis, Shanghai Hile Bio-Technology Co (SHSE:603718) is currently considered Possible Value Trap. The stock's GF Value™ is ¥4.24, compared to a current price of ¥2.90 — trading 31.6% below its estimated fair value. The current Return-on-Tangible-Equity is 6.00%, which is 18% below median its 10-year median of 7.33. Shanghai Hile Bio-Technology Co's overall GF Score™ is 50/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Shanghai Hile Bio-Technology Co (SHSE:603718), the current Return-on-Tangible-Equity is 6.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Shanghai Hile Bio-Technology Co (SHSE:603718) Overvalued in 2026?
Based on GuruFocus' analysis, Shanghai Hile Bio-Technology Co stock appears to be undervalued.
The current stock price of ¥2.90 is trading 31.6% below its estimated GF Value™ of ¥4.24.
GuruFocus considers Shanghai Hile Bio-Technology Co to be Possible Value Trap.
Key valuation signals for SHSE:603718:
Return-on-Tangible-Equity: 6.00% (18% below median its 10-year median of 7.33)
GF Value™: ¥4.24 vs. price of ¥2.90 (31.6% below fair value)
No single metric tells the full story. See the SHSE:603718 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Shanghai Hile Bio-Technology Co Ltd is a veterinary biological product manufacturer integrating research and development, production, sales, and service. The company has over 40 categories of poultry, livestock, and pets. The company provides services for the prevention of livestock diseases, improving the health of livestock and poultry, and improving the production efficiency of farmers, and is able to provide comprehensive solutions and an authoritative veterinary expert service system.
50GF Score
Get the complete analysis for SHSE:603718
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:603718 has been successfully added to your 
